Spark Therapeutics (ONCE) Misses Q3 EPS by 28c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. SPY
10. FISV

Go back to Spark Therapeutics (ONCE) Misses Q3 EPS by 28c

Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress

November 6, 2018 7:30 AM EST

PHILADELPHIA, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the third quarter of 2018 and recent business progress.

In the third quarter, we made significant progress with LUXTURNA® (voretigene neparvovec-rzyl) both in terms of sales growth and medical policy coverage expansion. We have also made important advancements in preparing for the Phase 3 run-in study of investigational SPK-8011 for hemophilia A before year end, said Jeffrey D. Marrazzo, chief executive officer of... More